Showing 3451-3460 of 7058 results for "".
- BE BOLD at 16 Weeks: Bimekizumab Outperforms Risankizumab for PsAhttps://practicaldermatology.com/news/bimekizumab-outperforms-risankizumab-for-psa/2487356/New data from the Phase 3 BE BOLD study show that bimekizumab (Bimzelx; UCB) achieved superior joint responses compared with risankizumab (Skyriz
- Review: Botulinum Toxin Shows Potential in Acne Treatmenthttps://practicaldermatology.com/news/systematic-review-highlights-botulinum-toxins-potential-in-acne-treatment/2487204/Botulinum toxin A may offer a potential adjunctive treatment option for both acne vulgaris and acne scarring, according to a recent systematic review published in the Journal of Drugs in Dermatology. Botulinum Toxin S
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- Global Skin Cancer Burden Projected to Rise Through 2050: Studyhttps://practicaldermatology.com/news/global-skin-cancer-burden-projected-to-rise-through-2050/2487086/A new research letter published online in JAMA Dermatology highlights widening global disparities in skin cancer burden and projects continued increases in melanoma, cutaneous squamous cell carcinoma (cSCC), and basal cell c
- Text-Messaging Program Improves Cardiovascular Risk Behaviors in Psoriasishttps://practicaldermatology.com/news/text-messaging-program-improves-cardiovascular-risk-behaviors-in-psoriasis/2487068/Structured text-messaging interventions were associated with an improvement cardiovascular risk-related behaviors and patient activation in adults with psoriasis, according to new study results published online in JAMA Dermatology.
- Analysis: Black Children Show Lower Dermatology Specialty Care Use Despite Higher Disease Frequencyhttps://practicaldermatology.com/news/black-children-show-lower-dermatology-use-despite-higher-disease-frequency/2486986/Black children had higher electronic health record (EHR)–derived frequencies of atopic dermatitis (AD), acne, and hidradenitis suppurativa compared with White children across 8 US children’s hospitals. Investigators for the multicenter cross-sectional study
- Aging Cohort Analysis IDs Predictors of Stronger Epidermal Barrier Functionhttps://practicaldermatology.com/news/aging-cohort-analysis-ids-predictors-of-stronger-epidermal-barrier-function/2486981/A large population-based analysis from the Baltimore Longitudinal Study of Aging identified several demographic factors associated with stronger skin barrier function, according to findings presented by Katrina Abuabara, MD, MSCE, and colleagues.
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://practicaldermatology.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- BPO Not Linked with Higher Malignancy Risk: Meta-analysishttps://practicaldermatology.com/news/bpo-not-linked-with-higher-malignancy-risk-meta-analysis/2486846/Benzoyl peroxide (BPO) use for acne vulgaris was not significantly associated with increased malignancy risk in a systematic review and meta-analysis of more than 4 million patients, accoriding to results from a new meta-analysis.